Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone
Jacob Engellau, Bruce Allen Bach(Amgen (United States)), Peter Reichardt(Helios Hospital Berlin-Buch), R. J. Grimer(Royal Orthopaedic Hospital), Edwin Choy(Massachusetts General Hospital), Robert M. Henshaw(Orthopedic Institute), Sant P. Chawla(Sarcoma Oncology Center), Ira Jacobs(Amgen (United States)), Leanne L. Seeger(UCLA Health), Amy Feng(Amgen (United States)), Michael O’Neal(Campbellsville University), Ada Braun(National Cancer Centre Japan), Zachary Roberts(Amgen (United States)), Hans Gelderblom(Leiden University Medical Center)
Cited by 56
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k